These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 24456625)

  • 1. Yellow fever vaccine-associated adverse events following extensive immunization in Argentina.
    Biscayart C; Carrega ME; Sagradini S; Gentile A; Stecher D; Orduna T; Bentancourt S; Jiménez SG; Flynn LP; Arce GP; Uboldi MA; Bugna L; Morales MA; Digilio C; Fabbri C; Enría D; Diosque M; Vizzotti C
    Vaccine; 2014 Mar; 32(11):1266-72. PubMed ID: 24456625
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adverse event reports following yellow fever vaccination.
    Lindsey NP; Schroeder BA; Miller ER; Braun MM; Hinckley AF; Marano N; Slade BA; Barnett ED; Brunette GW; Horan K; Staples JE; Kozarsky PE; Hayes EB
    Vaccine; 2008 Nov; 26(48):6077-82. PubMed ID: 18809449
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adverse events following yellow fever preventive vaccination campaigns in eight African countries from 2007 to 2010.
    Breugelmans JG; Lewis RF; Agbenu E; Veit O; Jackson D; Domingo C; Böthe M; Perea W; Niedrig M; Gessner BD; Yactayo S;
    Vaccine; 2013 Apr; 31(14):1819-29. PubMed ID: 23395587
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Surveillance system for adverse events following immunization against yellow fever in Burkina Faso in 2008. Good practice recommendations].
    Yaméogo TM; Breugelmans JG; Kambou JL; Badolo O; Tiendrebéogo S; Traoré E; Avokey F; Yactayo S
    Med Trop (Mars); 2009 Aug; 69(4):320-1. PubMed ID: 19725376
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety of the yellow Fever vaccine: a retrospective study.
    Nordin JD; Parker ED; Vazquez-Benitez G; Kharbanda EO; Naleway A; Marcy SM; Molitor B; Kuckler L; Baggs J
    J Travel Med; 2013; 20(6):368-73. PubMed ID: 24118538
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Yellow fever vaccination: how much is enough?
    Massad E; Coutinho FA; Burattini MN; Lopez LF; Struchiner CJ
    Vaccine; 2005 Jun; 23(30):3908-14. PubMed ID: 15917112
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adverse event reports following yellow fever vaccination, 2007-13.
    Lindsey NP; Rabe IB; Miller ER; Fischer M; Staples JE
    J Travel Med; 2016 May; 23(5):. PubMed ID: 27378369
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intrathecal antibody production in two cases of yellow fever vaccine associated neurotropic disease in Argentina.
    Pires-Marczeski FC; Martinez VP; Nemirovsky C; Padula PJ
    J Med Virol; 2011 Dec; 83(12):2208-12. PubMed ID: 22012730
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety of the yellow fever vaccine during the September 2001 mass vaccination campaign in Abidjan, Ivory Coast.
    Fitzner J; Coulibaly D; Kouadio DE; Yavo JC; Loukou YG; Koudou PO; Coulombier D
    Vaccine; 2004 Nov; 23(2):156-62. PubMed ID: 15531032
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neurological adverse events temporally associated to mass vaccination against yellow fever in Juiz de Fora, Brazil, 1999-2005.
    Fernandes GC; Camacho LA; Sá Carvalho M; Batista M; de Almeida SM
    Vaccine; 2007 Apr; 25(16):3124-8. PubMed ID: 17316927
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Active and passive surveillance of yellow fever vaccine 17D or 17DD-associated serious adverse events: systematic review.
    Thomas RE; Lorenzetti DL; Spragins W; Jackson D; Williamson T
    Vaccine; 2011 Jun; 29(28):4544-55. PubMed ID: 21549787
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of two yellow fever vaccines for routine immunization programs in Argentina.
    Ripoll C; Ponce A; Wilson MM; Sharif N; Vides JB; Armoni J; Teuwen DE
    Hum Vaccin; 2008; 4(2):121-6. PubMed ID: 18382132
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adverse events following immunization during mass vaccination campaigns at first introduction of a meningococcal A conjugate vaccine in Burkina Faso, 2010.
    Ouandaogo CR; Yaméogo TM; Diomandé FV; Sawadogo C; Ouédraogo B; Ouédraogo-Traoré R; Pezzoli L; Djingarey MH; Mbakuliyemo N; Zuber PL
    Vaccine; 2012 May; 30 Suppl 2():B46-51. PubMed ID: 22230584
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risk of yellow fever vaccine-associated viscerotropic disease among the elderly: a systematic review.
    Rafferty E; Duclos P; Yactayo S; Schuster M
    Vaccine; 2013 Dec; 31(49):5798-805. PubMed ID: 24079979
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunogenicity and safety of yellow fever vaccine among 115 HIV-infected patients after a preventive immunisation campaign in Mali.
    Sidibe M; Yactayo S; Kalle A; Sall AA; Sow S; Ndoutabe M; Perea W; Avokey F; Lewis RF; Veit O
    Trans R Soc Trop Med Hyg; 2012 Jul; 106(7):437-44. PubMed ID: 22627101
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Annual report: Surveillance of adverse events following immunisation in Australia, 2011.
    Mahajan D; Cook J; Dey A; Macartney K; Menzies RI
    Commun Dis Intell Q Rep; 2012 Dec; 36(4):E315-32. PubMed ID: 23330706
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Age-related risk of adverse events following yellow fever vaccination in Australia.
    Lawrence GL; Burgess MA; Kass RB
    Commun Dis Intell Q Rep; 2004; 28(2):244-8. PubMed ID: 15460963
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Surveillance of adverse events following immunisation: Australia 2002 to 2003.
    Lawrence G; Boyd I; McIntyre P; Isaacs D
    Commun Dis Intell Q Rep; 2004; 28(3):324-38. PubMed ID: 15574056
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adverse events following yellow fever vaccination in immunocompromised persons.
    Lara AN; Miyaji KT; Ibrahim KY; Lopes MH; Sartori AMC
    Rev Inst Med Trop Sao Paulo; 2021; 63():e13. PubMed ID: 33656136
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Surveillance of adverse events following immunisation: Australia, 2000-2002.
    Lawrence G; Menzies R; Burgess M; McIntyre P; Wood N; Boyd I; Purcell P; Isaacs D
    Commun Dis Intell Q Rep; 2003; 27(3):307-23. PubMed ID: 14510057
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.